| larotinib (Z650) / HEC Pharm |
NCT04415853: Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer |
|
|
| Recruiting | 3 | 416 | RoW | Lerotinib, Z650, Irinotecan/Tegafur, Irinotecan Hydrochloride Injection/Tegafur Gimeracil Oteracil Potassium Capsule | Sunshine Lake Pharma Co., Ltd. | Esophageal Cancer | 08/23 | 11/23 | | |
NCT06145308: Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing |
|
|
| Recruiting | 2 | 10 | RoW | Vedolizumab, larotinib or enttraitinib, antiandrogen drug treatment, leprerelin + bicalutamide ± Abiraterone 1000mg po qd, ESG401, small molecule multi-target tyrosine kinase inhibitors± Chemioterapy, apatinib or erlotinib, albumin paclitaxel with platinum, HR-positive group, PI3K mutant group, Homologous Recombination repair defect group, Nectin-4 ADC group, Ivoximab group, Apalolito vorellizumab group | Peking Union Medical College, Peking University Hospital of Stomatology | Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy | 07/26 | 07/26 | | |
NCT03888092: Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification |
|
|
| Completed | 1/2 | 81 | RoW | Z650, Larotinib | Sunshine Lake Pharma Co., Ltd. | Esophageal Squamous Cell Carcinoma | 12/22 | 12/22 | | |
| Completed | 1 | 24 | | Larotinib Mesylate Capsule 50 mg once daily ;Larotinib Mesylate Capsule 100 mg once daily ;Larotinib Mesylate Capsule 150 mg once daily ;Larotinib Mesylate Capsule 220 mg once daily ;Larotinib Mesylate Capsule 300 mg once daily ;Larotinib Mesylate Capsule 400 mg once daily ;Larotinib Mesylate Capsule 500 mg once daily ;Larotinib Mesylate Capsule 600 mg once daily | Jilin university first hosptal; Jilin university first hosptal, self-funding | advanced solid tumors | | | | |
NCT05059743: ADME Study of [14C]- Larotinib in Healthy Male Subjects |
|
|
| Completed | 1 | 6 | RoW | [14C]-Larotinib | Sunshine Lake Pharma Co., Ltd. | Healthy Adult Male Volunteers | 01/22 | 01/22 | | |
NCT05057949: A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants |
|
|
| Active, not recruiting | 1 | 32 | RoW | Larotinib, Z650, Rifampin, Rifampin Capsules, Itraconazole, Itraconazole Capsules | Sunshine Lake Pharma Co., Ltd. | Healthy Volunteers | 01/23 | 03/23 | | |
NCT05048368: Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function |
|
|
| Not yet recruiting | 1 | 32 | RoW | Larotinib | Sunshine Lake Pharma Co., Ltd. | Esophageal Cancer, Advanced Solid Tumor | 12/24 | 12/24 | | |
